Aeglea Biotherapeutics Inc. (AGLE) expects to raise $51.4 million in its upcoming IPO. Based in Austin, Texas, Aeglea Biotherapeutics is a biotechnology company developing enzyme-based therapeutics to treat disorders of metabolism and cancer.
AGLE will offer 3.5 million shares at an expected price range of $16 to $18. CRVS filed for the IPO on June 16, 2015.
Lead Underwriters: BMO Capital Markets, Cowen & Co., and UBS Investment Bank
Underwriters: Needham & Co., and Wedbush Securities
Business Summary: Biopharmaceutical Company Developing Engineered Enzymes to Treat Disorders of Metabolism and Cancer
Aeglea Biotherapeutics is a biopharmaceutical company that is developing engineered human enzymes to treat inborn errors of metabolism and cancer.
The company is developing AERase/AEB1102, which is an amino acid to treat the degradation of arginine in blood circulation. In addition, this candidate is expected to treat hyperargininemia and cancer. Other candidates in their pipeline include AECase/AEB3103, which is an engineered human cysteine-degrading enzyme that will address hematologic and solid malignancies; AEMase/AEB2109, which is an engineered human enzyme that degrades methionine in the system for the treatment of solid tumors; and AEB4104, which is another engineered human enzyme that will degrade homocysteine in blood circulation to treat an inborn error of metabolism called homocystinuria.
(aegleabio.com/pipeline)
In the field of oncology, AGLE is seeking to reduce amino acid blood levels below the normal range, which may disrupt certain cancers that depend upon specific amino acids.
Its candidate AEB1102 is currently in Phase 1 clinical trials to treat solid tumors, and the company expects to initiate further clinical trials to investigate other uses in 2016 and 2017. Its other product candidates are in non-clinical development.
Aeglea Biotherapeutics’ candidates have been in-licensed from the University of Texas, Austin, and the company retains global commercialization rights for all of its product candidates.
